{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Follicular+Lymphoma%2C+Mantle+Cell+Lymphoma&page=28", "query": { "condition": "Follicular Lymphoma, Mantle Cell Lymphoma", "page": 28 }, "page_size": 10 }, "pagination": { "page": 28, "page_size": 10, "total_count": 650, "total_pages": 65, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Follicular+Lymphoma%2C+Mantle+Cell+Lymphoma&page=29&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Follicular+Lymphoma%2C+Mantle+Cell+Lymphoma&page=27&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-17T05:22:21.432Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01403636", "title": "A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "SAR245409", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 167, "start_date": "2011-10", "completion_date": "2014-09", "has_results": false, "last_update_posted_date": "2016-03-17", "last_synced_at": "2026-10-17T05:22:21.432Z", "location_count": 12, "location_summary": "Los Angeles, California • Fort Meyers, Florida • Augusta, Georgia + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Fort Meyers", "state": "Florida" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Maywood", "state": "Illinois" }, { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01403636" }, { "nct_id": "NCT00406809", "title": "A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Chronic Lymphoid Leukemia", "Lymphoid Malignancies", "Non-Hodgkin's Lymphoma", "Follicular Lymphoma", "Mantle Cell Lymphoma", "Peripheral T-cell Lymphoma" ], "interventions": [ { "name": "ABT-263", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie (prior sponsor, Abbott)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 81, "start_date": "2006-11", "completion_date": "2016-10", "has_results": false, "last_update_posted_date": "2021-08-02", "last_synced_at": "2026-10-17T05:22:21.432Z", "location_count": 11, "location_summary": "Los Angeles, California • Bethesda, Maryland • Boston, Massachusetts + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00406809" }, { "nct_id": "NCT01748721", "title": "MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Nasal Type Extranodal NK/T-cell Lymphoma", "Anaplastic Large Cell Lymphoma", "Angioimmunoblastic T-cell Lymphoma", "Childhood Burkitt Lymphoma", "Childhood Diffuse Large Cell Lymphoma", "Childhood Immunoblastic Large Cell Lymphoma", "Childhood Nasal Type Extranodal NK/T-cell Lymphoma", "Cutaneous B-cell Non-Hodgkin Lymphoma", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Hepatosplenic T-cell Lymphoma", "Intraocular Lymphoma", "Nodal Marginal Zone B-cell Lymphoma", "Noncutaneous Extranodal Lymphoma", "Peripheral T-cell Lymphoma", "Post-transplant Lymphoproliferative Disorder", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Grade III Lymphomatoid Granulomatosis", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Adult T-cell Leukemia/Lymphoma", "Recurrent Childhood Anaplastic Large Cell Lymphoma", "Recurrent Childhood Grade III Lymphomatoid Granulomatosis", "Recurrent Childhood Large Cell Lymphoma", "Recurrent Childhood Lymphoblastic Lymphoma", "Recurrent Childhood Small Noncleaved Cell Lymphoma", "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Recurrent Small Lymphocytic Lymphoma", "Recurrent/Refractory Childhood Hodgkin Lymphoma", "Refractory Hairy Cell Leukemia", "Small Intestine Lymphoma", "Splenic Marginal Zone Lymphoma", "T-cell Large Granular Lymphocyte Leukemia", "Testicular Lymphoma", "Unspecified Adult Solid Tumor, Protocol Specific", "Unspecified Childhood Solid Tumor, Protocol Specific", "Waldenström Macroglobulinemia" ], "interventions": [ { "name": "anti-endosialin/TEM1 monoclonal antibody MORAb-004", "type": "BIOLOGICAL" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Morphotek", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Months", "maximum_age": "21 Years", "sex": "ALL", "summary": "13 Months to 21 Years" }, "enrollment_count": 27, "start_date": "2013-11", "completion_date": "2015-05", "has_results": false, "last_update_posted_date": "2016-01-08", "last_synced_at": "2026-10-17T05:22:21.432Z", "location_count": 20, "location_summary": "Birmingham, Alabama • Orange, California • San Francisco, California + 17 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01748721" }, { "nct_id": "NCT01238146", "title": "Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Nodal Marginal Zone B-cell Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Splenic Marginal Zone Lymphoma" ], "interventions": [ { "name": "bendamustine hydrochloride", "type": "DRUG" }, { "name": "obatoclax mesylate", "type": "DRUG" }, { "name": "rituximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2010-10", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-06-06", "last_synced_at": "2026-10-17T05:22:21.432Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01238146" }, { "nct_id": "NCT00014235", "title": "Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Acute Myeloid Leukemia/Transient Myeloproliferative Disorder", "Acute Undifferentiated Leukemia", "Adult Acute Lymphoblastic Leukemia in Remission", "Adult Acute Myeloid Leukemia in Remission", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Del(5q)", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Adult Nasal Type Extranodal NK/T-cell Lymphoma", "Anaplastic Large Cell Lymphoma", "Angioimmunoblastic T-cell Lymphoma", "Blastic Plasmacytoid Dendritic Cell Neoplasm", "Childhood Acute Lymphoblastic Leukemia in Remission", "Childhood Acute Myeloid Leukemia in Remission", "Childhood Burkitt Lymphoma", "Childhood Diffuse Large Cell Lymphoma", "Childhood Immunoblastic Large Cell Lymphoma", "Childhood Myelodysplastic Syndromes", "Childhood Nasal Type Extranodal NK/T-cell Lymphoma", "Chronic Myelomonocytic Leukemia", "Cutaneous B-cell Non-Hodgkin Lymphoma", "de Novo Myelodysplastic Syndromes", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Hepatosplenic T-cell Lymphoma", "Intraocular Lymphoma", "Juvenile Myelomonocytic Leukemia", "Mast Cell Leukemia", "Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable", "Nodal Marginal Zone B-cell Lymphoma", "Noncutaneous Extranodal Lymphoma", "Peripheral T-cell Lymphoma", "Post-transplant Lymphoproliferative Disorder", "Previously Treated Myelodysplastic Syndromes", "Primary Systemic Amyloidosis", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Grade III Lymphomatoid Granulomatosis", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Adult T-cell Leukemia/Lymphoma", "Recurrent Childhood Acute Lymphoblastic Leukemia", "Recurrent Childhood Acute Myeloid Leukemia", "Recurrent Childhood Anaplastic Large Cell Lymphoma", "Recurrent Childhood Grade III Lymphomatoid Granulomatosis", "Recurrent Childhood Large Cell Lymphoma", "Recurrent Childhood Lymphoblastic Lymphoma", "Recurrent Childhood Small Noncleaved Cell Lymphoma", "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Recurrent Small Lymphocytic Lymphoma", "Recurrent/Refractory Childhood Hodgkin Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Hairy Cell Leukemia", "Refractory Multiple Myeloma", "Small Intestine Lymphoma", "Splenic Marginal Zone Lymphoma", "Stage II Multiple Myeloma", "Stage III Multiple Myeloma", "T-cell Large Granular Lymphocyte Leukemia", "Testicular Lymphoma", "Untreated Adult Acute Lymphoblastic Leukemia", "Untreated Adult Acute Myeloid Leukemia", "Untreated Childhood Acute Lymphoblastic Leukemia", "Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies", "Waldenström Macroglobulinemia" ], "interventions": [ { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "total-body irradiation", "type": "RADIATION" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE", "OTHER" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "74 Years", "sex": "ALL", "summary": "Up to 74 Years" }, "enrollment_count": 160, "start_date": "2000-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2020-01-21", "last_synced_at": "2026-10-17T05:22:21.432Z", "location_count": 9, "location_summary": "Tucson, Arizona • Duarte, California • Stanford, California + 5 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Portland", "state": "Oregon" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00014235" }, { "nct_id": "NCT00088868", "title": "17-Dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in Treating Patients With an Advanced Solid Tumor or Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma", "Small Intestine Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "alvespimycin hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institutes of Health Clinical Center (CC)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2004-06", "completion_date": "2010-12", "has_results": false, "last_update_posted_date": "2012-03-15", "last_synced_at": "2026-10-17T05:22:21.432Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00088868" }, { "nct_id": "NCT00003874", "title": "Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Leukemia", "Lymphoma" ], "interventions": [ { "name": "monoclonal antibody CD19", "type": "BIOLOGICAL" }, { "name": "monoclonal antibody CD20", "type": "BIOLOGICAL" }, { "name": "in vitro-treated peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "70 Years", "sex": "ALL", "summary": "Up to 70 Years" }, "enrollment_count": null, "start_date": "1999-02", "completion_date": "2001-09", "has_results": false, "last_update_posted_date": "2011-11-29", "last_synced_at": "2026-10-17T05:22:21.432Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003874" }, { "nct_id": "NCT00003962", "title": "Interleukin-2 Following Bone Marrow Transplantation in Treating Patients With Hematologic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm" ], "interventions": [ { "name": "aldesleukin", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "65 Years", "sex": "ALL", "summary": "Up to 65 Years" }, "enrollment_count": null, "start_date": "1998-04", "completion_date": "2000-06", "has_results": false, "last_update_posted_date": "2014-05-02", "last_synced_at": "2026-10-17T05:22:21.432Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003962" }, { "nct_id": "NCT03833180", "title": "A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Mantle Cell Lymphoma", "Follicular Lymphoma", "Marginal Zone Lymphoma", "Diffuse Large B-cell Lymphoma", "Richter Transformation Lymphoma", "Burkitt Lymphoma", "Lymphoplasmacytoid Lymphoma", "T-cell Non-Hodgkin Lymphoma", "Acute Lymphoid Leukemia", "Acute Myeloid Leukemia", "Waldenstrom Macroglobulinemia" ], "interventions": [ { "name": "Zilovertamab vedotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 91, "start_date": "2019-03-14", "completion_date": "2023-12-18", "has_results": false, "last_update_posted_date": "2024-01-12", "last_synced_at": "2026-10-17T05:22:21.432Z", "location_count": 14, "location_summary": "Duarte, California • La Jolla, California • Los Angeles, California + 9 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "New Hyde Park", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03833180" }, { "nct_id": "NCT00003885", "title": "Arsenic Trioxide in Treating Patients With Recurrent or Refractory Acute Leukemia, Chronic Myeloide Leukemia, Myelodysplasia, Lymphoma, or Myeloma", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "arsenic trioxide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Our Lady of Mercy Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "1997-11", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-11-06", "last_synced_at": "2026-10-17T05:22:21.432Z", "location_count": 1, "location_summary": "The Bronx, New York", "locations": [ { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003885" } ] }